We will see next Thursday. I will just offer this comment: In the interim Gilead can flush all the ant-retrovirals they want down people’s throats but this next study is a not a chess draw, it is check-mate.

If Leronlimab shows both viral suppression (we already checked that box) AND immune modulation, without which patients subject themselves to related co-morbidities and premature mortality…with virtually no side effects…it would likely SUPPLANT existing multi-drug regimens with side effects sufficient to open the door to patient compliance issues and by extension drug resistance…and become STANDARD OF CARE. Monotherapy with a superior drug means you own the market.

Checkmate. Gilead might be forced to write a very big check to secure their franchise which will otherwise wither.

I stand by my comment, this protocol has to be bulletproof, it is of critical importance to Cytodyn’s future.